LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
- Your personalised programme is built around medical care, not willpower.
- No generic diets. No guesswork.
- Just science-backed results and expert support.
Find out if you’re eligible
Wegovy (semaglutide) and Eliquis (apixaban) are two distinct prescription medicines that may be prescribed together for patients managing both obesity and cardiovascular conditions. Wegovy is a GLP-1 receptor agonist used for chronic weight management, whilst Eliquis is a direct oral anticoagulant (DOAC) that prevents blood clots in conditions such as atrial fibrillation. No direct drug interaction exists between these medications, and concurrent use is not contraindicated. However, clinical considerations including gastrointestinal effects, renal function monitoring, and bleeding risk require careful assessment. This article examines the safety, interactions, and monitoring requirements when taking Wegovy and Eliquis together.
Quick Answer: Wegovy and Eliquis can be taken together safely as no direct drug interaction exists between semaglutide and apixaban.
Wegovy (semaglutide 2.4 mg) and Eliquis (apixaban) are two distinct prescription medications used to treat entirely different medical conditions, though patients with obesity and cardiovascular disease may require both simultaneously.
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. The medication works by mimicking the natural hormone GLP-1, which regulates appetite and food intake. Semaglutide slows gastric emptying, increases feelings of fullness, and reduces hunger signals in the brain. It is administered as a once-weekly subcutaneous injection, with doses gradually increased over 16–20 weeks to the maintenance dose of 2.4 mg. NHS use is more restricted than the marketing authorisation, with NICE (TA875) recommending semaglutide only within specialist weight management services for adults with a BMI of at least 35 kg/m² with a weight-related comorbidity, or ≥30 kg/m² with type 2 diabetes. NICE obesity guidance (CG189) recommends considering pharmacological interventions for weight management as part of a multicomponent approach including dietary modification and increased physical activity.
Eliquis, by contrast, is a direct oral anticoagulant (DOAC) that inhibits Factor Xa, a crucial enzyme in the blood clotting cascade. It is prescribed to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, to treat or prevent deep vein thrombosis (DVT) and pulmonary embolism (PE), and for prevention of VTE following hip or knee replacement surgery. The standard dose for atrial fibrillation is 5 mg twice daily, though this is reduced to 2.5 mg twice daily in patients meeting at least two of the following criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥133 micromol/L. Unlike warfarin, Eliquis does not require routine blood monitoring, though renal function should be assessed periodically as the drug is partially eliminated by the kidneys.
LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
Find out if you’re eligible
There is no official contraindication to taking Wegovy and Eliquis concurrently, and no direct pharmacological interaction between semaglutide and apixaban has been identified in clinical studies or post-marketing surveillance. The MHRA/EMC Summary of Product Characteristics (SmPC) for both medications does not list either drug as contraindicated when used together. The two medications work through entirely different mechanisms and are metabolised via separate pathways, which reduces the likelihood of direct drug-drug interactions.
Many patients prescribed anticoagulation therapy also have obesity or overweight as a cardiovascular risk factor. Indeed, weight management is an important component of comprehensive cardiovascular disease prevention. The European Medicines Agency (EMA) and MHRA product information for both medications does not include specific warnings about concurrent use.
However, it is essential to recognise that whilst no direct interaction exists, the gastrointestinal effects of Wegovy may have indirect implications for patients taking anticoagulants. Semaglutide commonly causes nausea, vomiting, and diarrhoea, particularly during dose escalation. These side effects could theoretically affect hydration status and nutritional intake, which may impact renal function and medication adherence, though this is not a documented interaction specific to apixaban.
It's important to note that while semaglutide and apixaban do not interact directly, apixaban does interact with strong inhibitors or inducers of both CYP3A4 and P-glycoprotein (such as ketoconazole, clarithromycin, carbamazepine, or St John's wort), which can significantly affect its blood levels.
Patients should always inform their healthcare provider about all medications they are taking, including over-the-counter medicines and supplements. Your GP or specialist will assess your individual circumstances, including your renal function, bleeding risk, and overall health status, before confirming that both medications are appropriate for you. Never start, stop, or change the dose of either medication without medical supervision.
Whilst Wegovy and Eliquis do not interact directly at a pharmacological level, several clinical considerations warrant attention when both medications are prescribed together.
Gastric emptying and medication absorption: Semaglutide significantly delays gastric emptying, which is part of its therapeutic mechanism for weight loss. Apixaban is primarily absorbed in the upper gastrointestinal tract, with absorption decreasing in the more distal regions of the GI tract. While there is currently no evidence that semaglutide-induced delayed gastric emptying significantly affects apixaban's clinical efficacy, the theoretical possibility exists. Apixaban's bioavailability is not significantly affected by food or gastric pH, which provides some reassurance regarding concurrent use with GLP-1 receptor agonists, though specific studies with semaglutide are limited.
Gastrointestinal side effects and bleeding risk: According to the Wegovy SmPC, common adverse effects include nausea (very common), diarrhoea (very common), vomiting (very common), and constipation (very common). Severe gastrointestinal symptoms could theoretically increase the risk of gastrointestinal bleeding in patients taking anticoagulants, though there is no evidence that semaglutide itself increases bleeding risk. This remains a theoretical concern that requires clinical vigilance rather than a documented interaction. Patients experiencing persistent vomiting or diarrhoea should contact their healthcare provider, as dehydration may affect renal function, which is relevant for apixaban elimination.
Weight loss effects on anticoagulation: Significant weight loss achieved with Wegovy may alter body composition and potentially affect the volume of distribution of medications. For apixaban in atrial fibrillation, dose reduction to 2.5 mg twice daily is recommended when patients meet at least two of three criteria, one being body weight ≤60 kg. Patients losing substantial weight should have their dosing reviewed if they approach this threshold, particularly if they also meet one of the other criteria (age ≥80 years or serum creatinine ≥133 micromol/L).
Cardiovascular benefits and risks: Both medications may offer cardiovascular benefits in appropriate patient populations. Semaglutide has demonstrated cardiovascular risk reduction in clinical trials (including the SELECT trial for the 2.4 mg dose), whilst apixaban prevents thromboembolic events. The combination may provide complementary benefits for patients with both obesity and atrial fibrillation or thromboembolic disease.
Before starting Wegovy whilst taking Eliquis, or vice versa, have a comprehensive discussion with your GP or specialist covering several important topics.
Your complete medication list: Provide an accurate, up-to-date list of all prescription medications, over-the-counter drugs, herbal supplements, and vitamins you take. Some supplements (such as fish oils, vitamin E, or ginkgo biloba) may increase bleeding risk when combined with anticoagulants, and your healthcare provider needs this complete picture.
Your medical history: Discuss your full medical history, particularly:
Previous bleeding episodes or bleeding disorders
History of gastrointestinal problems, including peptic ulcers, inflammatory bowel disease, or gastro-oesophageal reflux disease
Kidney function (apixaban requires dose adjustment based on specific criteria; both medications require caution in renal impairment)
History of pancreatitis (semaglutide should be used with caution; stop treatment if pancreatitis is suspected)
Diabetic retinopathy (semaglutide requires caution in this condition)
Pregnancy plans (both medications should be avoided in pregnancy)
Monitoring requirements: Clarify what monitoring you will need. For Eliquis, this typically includes renal function tests at baseline and at least annually (more frequently if you have chronic kidney disease, are elderly, or develop intercurrent illness). For Wegovy, monitoring may include blood glucose levels (especially if you have diabetes), heart rate, and assessment for signs of pancreatitis or gallbladder disease.
Warning signs to watch for: Ensure you understand the symptoms that require urgent medical attention, including:
Signs of bleeding (unusual bruising, blood in urine or stools, prolonged bleeding from cuts, severe headache)
Head injury (seek immediate medical attention if you experience a head injury while taking an anticoagulant)
Severe abdominal pain (potential pancreatitis)
Persistent nausea, vomiting, or diarrhoea
Signs of allergic reaction
Changes in vision (particularly relevant for patients with diabetes)
Perioperative management: Discuss the need to inform all healthcare professionals, including dentists, about your anticoagulant use before any procedures.
Realistic expectations: Discuss realistic weight loss goals with Wegovy and understand that it works best as part of a comprehensive lifestyle programme including dietary changes and increased physical activity, as recommended in NICE guidance.
When taking Wegovy and Eliquis together, implementing appropriate monitoring and safety measures helps ensure optimal outcomes and early detection of potential problems.
Regular medical reviews: Schedule follow-up appointments as recommended by your healthcare provider, typically every 3–6 months initially, then at least annually once stable. These appointments should include assessment of weight loss progress, review of side effects, renal function testing, and evaluation of your continued need for both medications. According to the Wegovy SmPC and NHS commissioning policies, treatment should be discontinued if a patient has not lost at least 5% of their initial body weight after 12 weeks on the maintenance dose of 2.4 mg.
Renal function monitoring: Both medications require attention to kidney function. Apixaban is partially eliminated renally, and dose reduction is necessary in patients with atrial fibrillation meeting at least two of three specific criteria (age ≥80 years, weight ≤60 kg, or serum creatinine ≥133 micromol/L). Apixaban should be used with caution in severe renal impairment (CrCl 15-29 mL/min) and is not recommended when CrCl is below 15 mL/min. Wegovy does not require dose adjustment in renal impairment but should be used with caution due to potential dehydration from gastrointestinal side effects. Your GP should check your renal function at baseline and periodically thereafter (at least annually, more frequently if you have reduced renal function).
Self-monitoring for adverse effects: Be vigilant for signs of bleeding, including unusual bruising, pink or brown urine, red or black stools, bleeding gums, nosebleeds that are difficult to stop, unusually heavy menstrual periods, or severe headache. Also monitor for Wegovy-related side effects, particularly severe abdominal pain (which could indicate pancreatitis), persistent nausea or vomiting, or signs of gallbladder problems.
Lifestyle and dietary considerations: Maintain adequate hydration, especially during the initial weeks of Wegovy when gastrointestinal side effects are most common. Avoid excessive alcohol consumption, which can increase bleeding risk with anticoagulants and may worsen gastrointestinal symptoms with semaglutide. Follow a balanced diet as recommended by your healthcare team.
Medication adherence: Take both medications exactly as prescribed. Wegovy is administered once weekly on the same day each week, whilst Eliquis is taken twice daily at approximately 12-hour intervals. Missing doses of Eliquis increases stroke risk, whilst inconsistent use of Wegovy reduces its effectiveness for weight management.
When to seek urgent medical attention: Contact your GP promptly or attend A&E if you experience signs of serious bleeding, severe persistent abdominal pain, continuous vomiting preventing oral intake, signs of allergic reaction (rash, swelling, difficulty breathing), or any other concerning symptoms. Always seek immediate medical attention if you experience a head injury while taking an anticoagulant. Always inform healthcare professionals treating you for any condition that you are taking both an anticoagulant and a weight management medication.
Yes, there is no official contraindication to taking Wegovy and Eliquis together, and no direct pharmacological interaction has been identified between semaglutide and apixaban. However, your healthcare provider should monitor for gastrointestinal effects and assess renal function regularly.
Wegovy does not directly affect Eliquis's anticoagulant action, though semaglutide delays gastric emptying which theoretically could influence medication absorption. Currently, no clinical evidence suggests this affects apixaban's efficacy, and the two medications are metabolised via separate pathways.
Regular renal function tests (at least annually), monitoring for bleeding signs, assessment of gastrointestinal side effects, and periodic weight checks are essential. Patients should attend follow-up appointments every 3–6 months initially, then at least annually once stable on both medications.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
